Sandbox 123

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
-
<StructureSection load= size=450 side='right' scene='36/365380/4dki_cartoon/16'>
+
<StructureSection load= size=450 side='right' scene='36/365380/4dki_cartoon/28'>
Transpeptidase (TP), also known as penicillin-binding proteins (PBP), catalyze the cross-linking of peptidoglycan polymers during bacterial cell wall synthesis. Beta-lactam (β-lactam) antibiotics, which
Transpeptidase (TP), also known as penicillin-binding proteins (PBP), catalyze the cross-linking of peptidoglycan polymers during bacterial cell wall synthesis. Beta-lactam (β-lactam) antibiotics, which
Line 13: Line 13:
== Structure of a Resistant Transpeptidase ==
== Structure of a Resistant Transpeptidase ==
-
Methicillin resistant Staphylococcus aureus (MRSA) is resistant to all β-lactams because it acquires an alternative PBP, PBP2a, that is not bound or inhibited by any β-lactams. PBP2a is composed of two domains: a <font color='orange'><b>non-penicillin binding domain </b><scene name='36/365380/4dki_cartoon/17'>(NPB) </scene></font> and a <font color='dodgerblue'><b>transpeptidase <scene name='36/365380/4dki_cartoon/18'>(TP)</scene> binding domain </b></font>. The NBP domain of PBP2a is anchored in the cell membrane, while the TP domain “sits” in the periplasm with its active site facing the inner surface of the cell wall. The active site contains <scene name='36/365380/Ser403/21'>a serine residue at position 403 (ser403)</scene> which catalyzes the cross-linking of the peptidoglycan rows with pentaglycine cross-links.
+
Methicillin resistant Staphylococcus aureus (MRSA) is resistant to all β-lactams because it acquires an alternative PBP, PBP2a, that is not bound or inhibited by any β-lactams. PBP2a is composed of two domains: a <font color='orange'><b>non-penicillin binding domain </b><scene name='36/365380/4dki_cartoon/29'>(NPB) </scene></font> and a <font color='dodgerblue'><b>transpeptidase <scene name='36/365380/4dki_cartoon/30'>(TP)</scene> binding domain </b></font>. The NBP domain of PBP2a is anchored in the cell membrane, while the TP domain “sits” in the periplasm with its active site facing the inner surface of the cell wall. The active site contains <scene name='36/365380/Ser403/22'>a serine residue at position 403 (ser403)</scene> which catalyzes the cross-linking of the peptidoglycan rows with pentaglycine cross-links.
Line 42: Line 42:
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
MRSA becomes resistant to β-lactams by acquiring an alternative PBP, PBP2a, that is
-
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – <scene name='36/365380/Ceftobiprole/4'>ceftobiprole</scene> and ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
+
neither bound nor inhibited by β-lactams. Recently, two cephalosporins – <scene name='36/365380/Ceftobiprole/28'>ceftobiprole</scene> and ceftaroline – that have anti-MRSA activity have been developed. Ceftobiprole is able to
-
inhibit PBP2a because additional chemical groups at the <scene name='36/365380/Ceftobiprole/12'>R2</scene> position of the cephalosporin backbone are able to interact with additional amino acid residues in PBP2a; specifically
+
inhibit PBP2a because additional chemical groups at the <scene name='36/365380/Ceftobiprole/29'>R2</scene> position of the cephalosporin backbone are able to interact with additional amino acid residues in PBP2a; specifically
-
<scene name='36/365380/Ceftobiprole/27'>Tyr446 and Met641</scene>. As a result of its tighter binding to PBP2a, ceftobiprole is able to more
+
<scene name='36/365380/Ceftobiprole/30'>Tyr446 and Met641</scene>. As a result of its tighter binding to PBP2a, ceftobiprole is able to more
efficiently react with the serine active site residue and therefore inhibit the activity of
efficiently react with the serine active site residue and therefore inhibit the activity of
PBP2a.
PBP2a.
Line 50: Line 50:
== PBP2a and Ceftaroline ==
== PBP2a and Ceftaroline ==
-
<scene name='36/365380/3zfz_1/3'>PBP2a in complex with Ceftaroline</scene> (PDB:3ZFZ)
+
<scene name='36/365380/3zfz_1/19'>PBP2a in complex with Ceftaroline</scene> (PDB:3ZFZ)
-
In addition to TP domain of PBP2a, there is an allosteric domain,highlighted orange, in which the distance between <scene name='36/365380/3zfz_1/17'>the active site and the allosteric site</scene> is 60Å.
+
In addition to TP domain of PBP2a, there is an allosteric domain,highlighted orange, in which the distance between <scene name='36/365380/3zfz_1/20'>the active site and the allosteric site</scene> is 60Å.
-
Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/18'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.
+
Allosteric site serves as a binding site for the substrate <scene name='36/365380/3zfz_1/7'>peptidoglycan</scene>. When the substrate binds to the <scene name='36/365380/3zfz_1/21'>allosteric site</scene> (Tyr105, Asn146, Asp295, Tyr297), a conformational change occurs at the active site, opening it and allowing catalytic action to occur.
-
The medicine, <scene name='36/365380/3zfz_1/12'>ceftaroline</scene>, mimics the substrate at the allosteric site opening the active site, allowing ceftaroline to <scene name='36/365380/3zfz_1/14'>enter and bind noncovalently</scene>.
+
The medicine, ceftaroline, mimics the substrate at the allosteric site opening the active site, allowing <scene name='36/365380/3zfz_1/22'>ceftaroline</scene> to <scene name='36/365380/3zfz_1/23'>enter and bind noncovalently</scene>.

Revision as of 21:26, 5 May 2014

Drag the structure with the mouse to rotate
Personal tools